Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biovitrum's new broom

Martin Nicklasson, who became president and CEO of Biovitrum AB in May, has unveiled plans to refocus the company's research and business activities away from primary care to exclusively focus on specialty care, an area where it's far easier for small companies to play.

The board of Biovitrum (SSE:BVT, Stockholm, Sweden) had asked Nicklasson to assess the company's diverse pipeline and portfolio, most of it inherited when it was spun out of Pharmacia AB in 2001. His first conclusions are that the company's portfolio is too diverse and that it would not have the critical mass to develop a sustainable business through products for the primary care

Read the full 1070 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers